Dynavax Technologies reported $52.77M in Sales Revenues for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13959M 949M
Adma Biologics ADMA:US $ 17.83M 1.78M
Agenus AGEN:US $ 10.73M 0.99M
Alexion Pharmaceuticals ALXN:US $ 1636.5M 44.7M
Amgen AMGN:US $ 6526M 625M
Astrazeneca AZN:US $ 8220M 900M
AstraZeneca AZN:LN 8220M 900M
Biogen BIIB:US $ 2775M 81M
Biomarin Pharmaceutical BMRN:US $ 501.69M 15.66M
BioSpecifics Technologies BSTC:US 11.26 7.35
Bristol Myers Squibb BMY:US $ 11703M 630M
Chimerix CMRX:US $ 0.39M 1.04M
Dynavax Technologies DVAX:US $ 52.77M 30.57M
Gilead Sciences GILD:US $ 6217M 206M
Glaxosmithkline GSK:US $ 8092M 674M
Gw Pharmaceuticals GWPH:US $ 152.47M 4.24M
Merk MRK:US $ 11402M 678M
Nektar Therapeutics NKTR:US $ 28.33M 4.68M
Neurocrine Biosciences NBIX:US $ 288.9M 52.3M
Novartis NOVN:VX SF 13294M 600M
Pfizer PFE:US $ 18977M 4395M
Regeneron Pharmaceuticals REGN:US $ 5138.5M 2609.8M
Sarepta Therapeutics SRPT:US $ 164.09M 17.16M
Tg Therapeutics TGTX:US $ 1.54M 0.75M
Vertex Pharmaceuticals VRTX:US $ 1793.37M 69.06M